Role of additional angiography and chemoembolization in patients with hepatocellular carcinoma who achieved complete necrosis following transarterial chemoembolization
Myoung Kuk Jang, Dong Jin Suh(Daehang Hospital), Young–Hwa Chung(Jeju National University Hospital), Kyu‐Bo Sung(Ulsan College), In‐Sook Kim(Frederick National Laboratory for Cancer Research), Hyun‐Ki Yoon(SingHealth), Young‐Suk Lim(Asan Medical Center), Yung Sang Lee(The University of Texas at Dallas), Ah Young Kim(Korea Institute of Radiological and Medical Sciences), G.B. Ko(Ulsan College), Han Chu Lee(Asan Medical Center)
Cited by 15
Related Papers
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|The Lancet Oncology|2015|1.1k
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653
Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine
|Journal of Lipid Research|2007|595
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
|European Journal of Cancer|2011|573